Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,101
datasets available to search
ShareScore release 0.9.0
Dataset results
3,101 results for “tables”
Table 2 in Genus-level revision of the Alycaeidae (Gastropoda, Cyclophoroidea), with an annotated species catalogue
<p><b>Table 2.</b> Genus-group taxa of the Alycaeidae. Abbreviations: M: monotypy, OD: original designation, SD: subsequent designation. Valid genera are marked with an asterisk.</p><table><tbody><tr><th>Genus</th><th>Type species</th><th>Mode of designation</th><th>Remarks</th></tr></tbody><tbody><tr><td>* <i>Alycaeus</i> Gray, 1850</td><td><i>Cyclostoma gibbum</i> Eydoux, 1838 (= <i>Alycaeus eydouxi</i> Venmans, 1956)</td><td>SD</td><td>accepted</td></tr><tr><td><i>Awalycaeus</i> Kuroda, 1951</td><td><i>Awalycaeus abei</i> Kuroda, 1951</td><td>M</td><td>synonym of <i>Dicharax</i></td></tr><tr><td>* <i>Chamalycaeus</i> Möllendorff 1897</td><td>Alycaeus (Chamalycaeus) fruhstorferi Möllendorff, 1897</td><td>M</td><td>accepted</td></tr><tr><td><i>Charax</i> Benson, 1859</td><td><i>Alycaeus hebes</i> Benson, 1857</td><td>SD</td><td>accepted name is <i>Dicharax</i></td></tr><tr><td><i>Cipangocharax</i> Kuroda, 1943</td><td><i>Alycaeus biexcisus</i> Pilsbry, 1902</td><td>M</td><td>synonym of <i>Dicharax</i></td></tr><tr><td><i>Cycloryx</i> Godwin-Austen, 1914</td><td><i>Cyclostoma constrictum</i> Benson, 1851</td><td>OD</td><td>synonym of <i>Pincerna</i></td></tr><tr><td>* <i>Dicharax</i> Kobelt & Möllendorff, 1900</td><td><i>Alycaeus hebes</i> Benson, 1857</td><td>SD</td><td>accepted</td></tr><tr><td>* <i>Dioryx</i> Benson, 1859</td><td><i>Alycaeus amphora</i> Benson, 1856</td><td>SD</td><td>accepted</td></tr><tr><td>* <i>Metalycaeus</i> Pilsbry, 1900</td><td>Alycaeus (Metalycaeus) melanopoma Pilsbry, 1900</td><td>SD</td><td>accepted</td></tr><tr><td><i>Orthalycaeus</i> L. Pfeiffer, 1876</td><td><i>Cyclostoma gibbum</i> Eydoux, 1838 (= <i>Alycaeus eydouxi</i> Venmans, 1956)</td><td>SD</td><td>synonym of <i>Alycaeus</i></td></tr><tr><td>* <i>Pincerna</i> Preston, 1907</td><td>Alycaeus (Pincerna) liratula Preston, 1907</td><td>M</td><td>accepted</td></tr><tr><td><i>Raptomphalus</i> Godwin-Austen, 1914</td><td>Alycaeus (Raptomphalus) magnificus Godwin-Austen, 1914</td><td>M</td><td>synonym of <i>Metalycaeus</i></td></tr><tr><td><i>Sigmacharax</i> Kuroda, 1943</td><td>Chamalycaeus (Sigmacharax) itonis Kuroda, 1943</td><td>M</td><td>synonym of <i>Dicharax</i></td></tr><tr><td>* <i>Stomacosmethis</i> Bollinger, 1918</td><td>Alycaeus (Stomacosmethis) sarasinorum Bollinger, 1918</td><td>SD</td><td>accepted</td></tr></tbody></table>
Table 5 in Genus-level revision of the Alycaeidae (Gastropoda, Cyclophoroidea), with an annotated species catalogue
<p><b>Table 5.</b> Distribution of genera in the three regions with high diversity. Double asterisks indicate relatively high taxon diversity of that given genus.</p><table><tbody><tr><th></th><th>Peninsular Malaysia and Sumatra</th><th>Northern Vietnam, northern Laos and southern China</th><th>Southeastern Himalaya</th></tr></tbody><tbody><tr><td><i>Alycaeus</i></td><td>*</td><td>*</td><td></td></tr><tr><td><i>Chamalycaeus</i></td><td>*</td><td></td><td>*</td></tr><tr><td><i>Dicharax</i></td><td>*</td><td>**</td><td>**</td></tr><tr><td><i>Dioryx</i></td><td></td><td>**</td><td>*</td></tr><tr><td><i>Metalycaeus</i></td><td></td><td>*</td><td>*</td></tr><tr><td><i>Pincerna</i></td><td>**</td><td>*</td><td>**</td></tr><tr><td><i>Stomacosmethis</i></td><td>**</td><td></td><td></td></tr></tbody></table>
Supplemental Table S1 Summary of clinical, histological and immunohistochemical results
Open the record for dataset details and reuse information.
Supplementary Figures and Tables
Open the record for dataset details and reuse information.
Supplementary File 12: Tables of direct, indirect and networks estimates and Forests plots of pairwise comparisons for all secondary outcomes
Open the record for dataset details and reuse information.
F2R polymorphisms and clopidogrel efficacy and safety in patients with minor stroke or TIA: supplemental figures and tables
<p><b>Objective</b>: To investigate the association between protease-activated receptors-1 (PAR-1) gene<i> F2R</i> polymorphisms and efficacy of clopidogrel for minor stroke or transient ischemic attack (TIA).</p> <p><b>Methods</b>: Three single-nucleotide polymorphisms (<i>CYP2C19*2</i> [681G>A, rs4244285], <i>CYP2C19</i>*<i>3</i> [636G>A, rs4986893] and <i>F2R</i> [IVSn-14 A/T, rs168753] were genotyped among<span> 2,924 patients randomized to clopidogrel plus aspirin (n=1461) or aspirin alone (n=1463). </span>The primary efficacy outcome was new stroke (ischemic or hemorrhagic) and the safety outcome was any bleeding.</p> <p><b>Results: </b>Overall, 859(29.4%) were AA homozygotes, 1479(50.6%) were AT heterozygotes and 586(20.0%) were TT homozygotes for <i>F2R</i> IVSn -14 polymorphisms; 1716 (58.7%) were carriers of at least one<i> CYP2C19</i> loss-of-function allele (*2 or *3). Compared with aspirin alone, patients with clopidogrel-aspirin treatment had a low risk of new stroke in patients with AT genotype (7.6% <i>vs.</i> 11.3%; hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.44-0.89) and TT genotype (5.8% <i>vs.</i> 11.6%; HR, 0.46; 95% CI, 0.25-0.82) but not in carriers of the AA genotype (10.8% <i>vs.</i> 11.6%; HR, 0.95; 95% CI, 0.63-1.44) (p=0.03 for interaction). The association between <i>F2R</i> IVSn -14 A/T polymorphism and clopidogrel response was present regardless of the carrier status of the <i>CYP2C19</i> loss-of-function alleles. The<i> F2R</i> IVSn -14 genotypes were not associated with the risk of any bleeding for clopidogrel-aspirin treatment (P=0.66 for interaction).</p> <p><span><b>Conclusions:</b><b> </b></span>Among patients with minor ischemic stroke or TIA who were receiving clopidogrel and aspirin, those carrying <i>F2R</i> IVSn -14 T allele had a lower rate of recurrent stroke than those who were not.</p> <p><span><b>Clinicaltrials.gov Identifier:</b></span> NCT00979589.</p>
Supplementary Table 1
<p>Supplementary Table 1</p>
Table 3
<p>It is supplemental Table 3.</p>
Table 1
<p>It is supplemental Table 1.</p>
Table 2
<p>It is supplemental Table 2.</p>
High-Pressure XAFS Measurements of the Coordination Environments of Fe2+ and Fe3+ in Basaltic Glasses (Table S1 & S2)
<p>Supplementary Information Table S1 & S2</p>
Global gene expression analysis of Streptococcus agalactiae at exponential growth phase_Table 2
<p>Top-100 most expressed genes by functional category.</p>
OTUs Table and fastq sequences from environmental DNA applied to trematode communities
<p>This OTUs table and fastq sequences underlie the main results of the study "Make visible the invisible: Optimized development of an environmental DNA metabarcoding tool for the characterization of trematode parasitic communities".</p> <p>In this study, our aim was to develop an optimized eDNA-based metabarcoding approach to detect trematodes and characterize their communities, most of which associated to aquatic environments. We thus assessed the ability of our eDNA-based metabarcoding approach to reconstruct trematode communities compared to a classical trematode monitoring method over four freshwater aquatic ecosystems. </p> <p>We focused on 4 natural sites from Occitanie Region (Southern France) that differ in terms of habitats, and in which the trematode communities were previously at least partially characterized. At each of these sites, we sampled the water-sediment interface from which the eDNA was extracted and sequenced with a MiSeq amplicons sequencing approach. <br> Over the four natural ecosystems screened in nature, 33 OTUs were generated from the eDNA-based approach, from which 11 trematode species were identified. In comparison, we identified five trematode species using the classical monitoring method, three of which were also detected by the eDNA-based approach.</p>
Table 2
<p>List of finds from Starbios2</p>
Supplementary Tables
<p>Supplementary Tables for DIQ<strong> </strong></p>
ENVIRONMENTAL MANAGEMENT FOR SUSTAINABLE BUSINESS DEVELOPMENT. Table 1
<p>Table 1, Four environmental strategies</p>
Table S1. Research papers and reviews about the effects of UV radiation on bryophytes
<p>Table S1. Research papers and reviews about the effects of UV radiation on bryophytes</p>
Repurposing Domperidone in Secondary Progressive MS - A Simon 2-Stage Phase 2 Futility Trial - Table e1: Results of the binary logistic regression model
<p><b>Objective:</b> To assess whether treatment with the generic drug domperidone can reduce the progression of disability in secondary progressive multiple sclerosis (SPMS), we conducted a phase 2 futility trial following the Simon two-stage design.</p> <p><b>Methods:</b> We enrolled patients in an open-label, Simon two-stage, single-center, phase 2, single-arm futility trial at the Calgary MS Clinic if they met the following criteria: age 18 to 60 years, SPMS, screening EDSS score of 4.0 to 6.5 and screening T25FW of 9 seconds or more. Patients received domperidone 10mg QID for one year. The primary outcome was worsening of disability, defined as worsening of the T25FW performance by 20% or more at 12 months compared to at baseline. This trial is registered with ClinicalTrials.gov, number NCT02308137.</p> <p><b>Results:</b> Between February 13<sup>th</sup>, 2015 and January 3<sup>rd</sup>, 2020, 110 patients were screened, 81 received treatment, 64 completed follow-up, of whom 62 were analysed. The study did not meet its primary endpoint: 22 of 62 (35%) patients experienced significant worsening of disability, which is close to the expected proportion of 40%, and above the pre-defined futility threshold. Patients with higher prolactin levels during the study had a significantly lower risk of disability progression, which may warrant further investigation. Domperidone treatment was reasonably well tolerated, but adverse events occurred in 84% and serious adverse events in 15% of patients.</p> <p><b>Conclusions:</b> Domperidone treatment could not reject futility in reducing disability progression in SPMS. The Simon two-stage trial model may be a useful model for phase 2 studies in progressive MS.</p> <p><b>Classification of Evidence:</b> This study provides Class III evidence that in individuals with secondary progressive multiple sclerosis participating in a futility trial, domperidone treatment could not reject futility in reducing disability progression at 12 months.</p>
Feature table of nearly 330k 16S V4 rRNA microbiome samples
<p>Feature table of nearly 330k 16S V4 rRNA microbiome samples</p>
Supplementary Data Tables for Stolper et al. (2022) Constraints on Early Paleozoic deep-ocean oxygen concentrations from the iron geochemistry of the Bay of Islands ophiolite in G-Cubed
<p>Supplementary data tables for Stolper et al. (2022) associated with the paper entitled "Constraints on Early Paleozoic deep-ocean oxygen concentrations from the iron geochemistry of the Bay of Islands ophiolite" published in <em>G-Cubed</em>.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.